Abstract
Background: Gallbladder stones are one of the most common of today's health-related problems. Prediction of Common Bile Duct Stones (CBDS) permits better management of those patients.
Objective: The aim of this study was to determine the sensitivity and specificity of various predictors of CBDS.
Methods: This cross-sectional study was conducted on patients who underwent Endoscopic Retrograde Cholangiopancreatography (ERCP) for suspected CBDS at King Fahd Hospital of the University (Al-Khobar, Saudi Arabia from 2006 to 2018. Based on the presence or absence of specific predictive features as per the American Society for Gastrointestinal Endoscopy (ASGE) guidelines, we stratified the patients into high, intermediate, and low-risk of harboring CBDS. Data were analyzed by IBM© SPSS© version 21, using Chi-square test, Mann–Whitney U test, Wilcoxon signed rank test, and receiver operating characteristic curve analysis. Also, binary logistic regression was performed to determine the independent predictors, and p-value <0.05 was considered statistically significant. Sensitivity, specificity, likelihood ratios, accuracy, positive predictive value, and negative predictive value were calculated for potential predictors of CBD stones. 
Results: One hundred forty-two patients were included in the study, 76 patients (53.5%) had choledocholithiasis [64.4% males, 45.8% females (p=0.028)] and 66 patients (46.5%) had normal CBD on endoscopic retrograde cholangiopancreatography. In the choledocholithiasis group, the proportion of jaundice was significantly higher 61% (p=0.037), abdominal pain was reported in 54.7% of the patients (p=0.126), itching in 75% (p=0.119), change in the color of stool and urine was reported in 57.1% (p=0.718), 61.4% (p=0.209) of the patients, respectively. Positive Murphy's sign was seen in 37.4% of the patients who had CBDS (p=0.234). Visualization of CBD stones on trans-abdominal ultrasonography was the best predictor for the presence of CBDS (adjusted OR: 4.744, sensitivity: 34%, specificity: 92%, p<0.0001), followed by CBD diameter (adjusted OR: 1.350, sensitivity: 82%, specificity: 49%, p=0.000). Among Liver function tests (LFTs), total bilirubin >1.8 mg/dl, direct bilirubin >2 mg/dl, GGTP >281 U/L, and ALP >149 U/L are considered reliable predictors for choledocholithiasis.
Conclusion: Visualization of CBD stones on trans-abdominal ultrasonography was the best predictor for the presence of CBDS followed by CBD diameter. CBD diameter ≥7 mm on ultrasonography in cases that the patient did not undergo cholecystectomy and more than 1 cm in cases that the patient underwent cholecystectomy are suggestive of CBDS. In presence of either conditions, we suggest proceeding to more invasive and therapeutic procedures such as ERCP.
 
Keywords: Gallstones, Common Bile Duct; Liver Function Tests; Ultrasonography; Jaundice

 

» HTML Fulltext    » PDF Fulltext    » doi: 10.19082/7610
Chuck Taylor All Star

Current Issue

Volume 12, issue 2, April-June 2020

 


 

The worldwide spread of COVID-19 as an emerging, rapidly evolving situation, and the dramatic need of urgent medicine or vaccine, has rapidly brought new hypotheses for pathophysiology and potential medicinal agents to the fore. It is crucial that the research community provide a way to publish this research in a timely manner.

To contribute to this important public health discussion, the Electronic Physician Journal is excited to announce a fast-track procedure to help researchers publish their articles on COVID-19 related subjects that fall under the broad definition of public health, internal medicine, and pharmacology. We are especially welcome to all hypotheses about the pathological basis of the COVID-19 infection and the possible characteristics of potential medicine and vaccine. Submit your manuscript here


 

The 6th World Conference on Research Integrity (WCRI) is to be held on June 2-5, 2019 in Hong Kong.

The WCRI is the largest and most significant international conference on research integrity. Since the first conference in Lisbon in 2007, it has given researchers, teachers, funding agencies, government officials, journal editors, senior administrators, and research students opportunities to share experiences and to discuss and promote integrity in research. Read more:


 

TDR Clinical Research and Development Fellowships

Call for applications

Deadline for submission: 7 March 2019, 16:00 (GMT)

TDR provides fellowships for early- to mid-career researchers and clinical trial staff (e.g. clinicians, pharmacists, medical statisticians, data managers, other health researchers) in low- and middle-income countries (LMICs) to learn how to conduct clinical trials. Read more:


Meta-Analysis Workshops in New York, USA, and London, UK, in April and May 2019

Don't miss this exceptional opportunity to learn how to perform and report a Meta-analysis correctly. Two Meta-analysis workshops are organized in April and May 2019 by Dr. Michael Borenstein in New York, USA (April 08-10, 2019) and London, UK (May 27-29).

About the Instructor

Dr. Michael Borenstein, one of the authors of Introduction to Meta-Analysis, is widely recognized for his ability to make statistical concepts accessible to researchers as well as to statisticians. He has lectured widely on meta-analysis, including at the NIH, CDC, and FDA. Read more: